Yuqin Song 1, Ke-Shu Zhou 2, Dehui Zou 3, Jianfeng Zhou 4, Jianda Hu 5, Haiyan Yang 6, Huilai Zhang 7, Jie Ji 8, Wei Xu 9, Jie Jin 10, Fangfang Lv 11, Ru Feng 12, Sujun Gao 13, Haiyi Guo 14, Lei Zhou 14, Rebecca Elstrom 15, Jane Huang 15, William Novotny 15, Rachel Wei 16, Jun Zhu 17#，Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma With Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase,Clin Cancer Res .,clincanres.3703.2019.

Yuqin Song 1 , Jianqiu Wu 2 , Xinchuan Chen 3 , Tongyu Lin 4 , Junning Cao 5 , Yanyan Liu 6 , Yaozhong Zhao 7 , Jie Jin 8 , Haiwen Huang 9 , Jianda Hu 10 , Jun Luo 11 , Liling Zhang 12 , Hongwei Xue 13 , Qingyuan Zhang 14 , Weiwei Wang 15 , Chunxia Chen 16 , Jifeng Feng 17 , Jun Zhu*, A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma,Clin Cancer Res.,Clin Cancer Res . 2019 Dec 15;25(24):7363-7369.

Wang X, Song Y, Chen W, Ding N, Liu W, Xie Y, Wang Y, Zhu J, Zeng C. Germline variants of DNA repair genes in early onset mantle cell lymphoma. Oncogene. 2021 Jan;40(3):551-563. doi: 10.1038/s41388-020-01542-2. Epub 2020 Nov 15. PMID: 33191405.,Oncogene,2021 Jan;40(3):551-563

Hu Y*, Wang D, Wang H, Zhao R, Wang Y, Shi Y, Zhu J, Xie Y#, Song YQ#, Lu H#. An urchin-like helical polypeptide-asparaginase conjugate with mitigated immunogenicity. Biomaterials. 2021 Jan;268:120606. doi: 10.1016/j.biomaterials.2020.120606. Epub 2020 Dec 17. PMID: 33360506.,j.biomaterials,2020.120606. Epub 2020 Dec 17.

Yuqin Song 1, Quanli Gao 2, Huilai Zhang 3, Lei Fan 4, Jianfeng Zhou 5, Dehui Zou 6, Wei Li 7, Haiyan Yang 8, Ting Liu 9, Quanshun Wang 10, Fangfang Lv 11, Haiyi Guo 12, Liudi Yang 12, Rebecca Elstrom 13, Jane Huang 13, William Novotny 13, Vivian Wei 12, Jun Zhu*, Treatment of Relapsed or Refractory Classical Hodgkin Lymphoma With the anti-PD-1, Tislelizumab: Results of a Phase 2, Single-Arm, Multicenter Study,Leukemia,Leukemia . 2019，August ;34(2):533-542.

Shi C, Li X, Wang X, Ding N, Ping L, Shi Y, Mi L, Lai Y, Song Y*, Zhu J*.The proto-oncogene Mer tyrosine kinase is a novel therapeutic target in mantle cell lymphoma.,J Hematol Oncol,11(1):43

Li J, Ding N, Wang X, Mi L, Ping L, Jin X, Liu Y, Ying Z, Xie Y, Liu W, Song Y*, Zhu J*. EP300 single nucleotide polymorphism rs20551 correlates with prolonged overall survival in diffuse large B cell lymphoma patients treated with R-CHOP.,Cancer Cell Int ,17:70

Li J, Wang X, Xie Y, Ying Z, Liu W, Ping L, Zhang C, Pan Z, Ding N*, Song Y*, Zhu J*. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.,Int J Cancer,142(1):202-213

Ping L#, Ding N#, Shi Y, Feng L, Li J, Liu Y, Lin Y, Shi C, Wang X, Pan Z, Song Y*, Zhu J*. The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages.,Oncotarget ,8(24):39218-39229

Liu Y, Wang X, Ding N, Mi L, Ping L, Jin X, Li J, Xie Y, Ying Z, Liu W, Zhang C, Deng L, Song Y*, Zhu J*. TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP.,BMC Cancer ,17(1):743

Sun Y#, Zhao X#, Ding N#, Gao H#, Wu Y, Yang Y, Zhao M, Hwang J, Song Y, Liu W*, Rao Y*. PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies.,Cell Research,28(7):779-781

Liu Y, Wang X, Deng L, Ping L, Shi Y, Zheng W, Lin N, Wang X, Tu M, Xie Y, Liu W, Ying Z, Zhang C, Pan Z, Wang X, Ding N*, Song Y*, Zhu J*. ITK inhibition induced in vitro and in vivo anti-tumor activity through downregulating TCR signaling pathway in malignant T cell lymphoma.,Cancer Cell Int,19:32

He Y, Li J, Ding N, Wang X, Deng L, Xie Y, Ying Z, Liu W, Ping L, Zhang C, Song Y*, Zhu J*. Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma.,J Exp Clin Cancer Res,38(1):86

Liu W, Liu J, Song Y, Wang X, Zhou M, Wang L*, Ma J*, Zhu J*; Union for China Leukemia Investigators of the Chinese Society of Clinical Oncology, Union for China Lymphoma Investigators of the Chinese Society of Clinical Oncology.Mortality of lymphoma and myeloma in China, 2004-2017: an observational study.,J Hematol Oncol,12(1):22

Sun Y#, Ding N#, Song Y#, Yang Z, Liu W*, Zhu J*, Rao Y*.Degradation of Bruton's tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas.,Leukemia,

Hong X#, Song Y#, Huang H, Bai B, Zhang H, Ke X, Shi Y, Zhu J*, Lu G, Liebscher S, Cai C.Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study.,Target Oncol,

Ying Z#, Huang XF#, Xiang X, Liu Y, Kang X, Song Y, Guo X, Liu H, Ding N, Zhang T, Duan P, Lin Y, Zheng W, Wang X, Lin N, Tu M, Xie Y, Zhang C, Liu W, Deng L, Gao S, Ping L, Wang X, Zhou N, Zhang J, Wang Y, Lin S, Mamuti M, Yu X, Fang L, Wang S, Song H, Wang G, Jones L, Zhu J*, Chen SY*. A safe and potent anti-CD19 CAR T cell therapy.,Nature Medicine,

Liu W#, Yang Y, Qi S, Wang Y, He X, Zhang L, Qu B, Qian L, Hou X, Qiao X, Wang H, Li G, Zhang Y, Zhu Y, Cao J, Wu J, Wu T, Zhu S, Shi M, Xu L, Su H, Lin N, Zhu J, Li Y, Song Y.* Treatment, Survival, and Prognosis of Advanced-Stage Natural Killer/T-Cell Lymphoma: An Analysis From the China Lymphoma Collaborative Group. Front Oncol. 2021 Feb 19;10:583050,Front Oncol.,2021 Feb 19;10:583050

DNA修复基因胚系突变在非霍奇金B细胞淋巴瘤-多肿瘤家系的研究, 课题负责人 , 2020.1.1～2022.12.1, 北京市自然科学基金 面上项目

DNA修复基因胚系突变在淋巴瘤多肿瘤家系的研究, 课题负责人 , 2019.9.1～2023.12.1, 国家自然科学基金面上项目

B细胞淋巴瘤BTK/Stat3基因突变与BTK抑制剂疗效的相关性研究, 课题负责人 , 2017.1.1～2020.12.31, 国家自然科学基金面上项目 编号81670187

研究生招生计划

招生年度	招生专业	学位级别	学位类型	研究方向	选拔方式
2022	肿瘤学	博士	科学学位	淋巴瘤转化研究	申请考核制
2022	肿瘤内科学	硕士	专业学位	临床技能训练与研究	全国统考
2022	肿瘤内科学	长学制	专业学位	临床技能训练与研究	长学制二级学科培养
2022	肿瘤内科学	博士	专业学位	临床技能训练与研究	申请考核制